Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients who failed immunotherapy: targeted drug combo trial launches

NCT ID NCT03334617

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the unique markers (biomarkers) in each person's tumor. The goal is to see which treatments are safe and effective for different types of lung cancer. About 528 adults are taking part in this phase 2 trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

528 people

The number who actually took part.

Started

Dec 2017

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * At least 18 years of age at the time of signing the informed consent form. * Participant must have histologically or cytologically confirmed metastatic or locally advanced and recurrent non-small-cell lung cancer (NSCLC) which is progressing. * Participants eligible for second- or later-line therapy, who must have received an anti-programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. Prior durvalumab is acceptable. The participant must have had disease progression on a prior line of anti-PD-1/PD-L1 therapy. * Eastern Cooperative Oncology Group/World Health Organization (ECOG/WHO) performance status of 0 to 1, and a minimum life expectancy of 12 weeks. * Participant must have at least 1 lesion that can be accurately measured. A previously irradiated lesion can be considered a target lesion if the lesion has clearly progressed. * Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal participants. Exclusion Criteria: * Participants whose tumour samples have targetable alterations in epidermal growth factor receptor (EGFR) and/or anaplastic lymphoma kinase (ALK) at initial diagnosis are excluded. In addition, participants whose tumour samples are known to have targetable alterations in ROS1, BRAF, MET or RET, are to be excluded. * Active or prior documented autoimmune or inflammatory disorders. * Active infection including tuberculosis, hepatitis B (known positive hepatitis B virus \[HBV\] surface antigen \[HBsAg\] result), hepatitis C, or human immunodeficiency virus (positive human immunodeficiency virus \[HIV\] 1/2 antibodies). * Female participant who are pregnant or breastfeeding, or male or female participants of reproductive potential who are not willing to employ effective birth control. * Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients, or history of severe hypersensitivity reactions to other monoclonal antibodies. * Participant has spinal cord compression or symptomatic brain metastases. * Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Participants may receive treatment with bisphosphonates or receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone metastases. * History of active primary immunodeficiency.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    Fullerton, California, 92835, United States

  • Research Site

    La Jolla, California, 92093, United States

  • Research Site

    Los Angeles, California, 90095, United States

  • Research Site

    Washington D.C., District of Columbia, 20016, United States

  • Research Site

    Chicago, Illinois, 60637, United States

  • Research Site

    Baltimore, Maryland, 21224, United States

  • Research Site

    Baltimore, Maryland, 21287, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    New York, New York, 10032, United States

  • Research Site

    Philadelphia, Pennsylvania, 19111, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Nashville, Tennessee, 37212, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Innsbruck, 6020, Austria

  • Research Site

    Salzburg, 5020, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Vienna, 1210, Austria

  • Research Site

    Edmonton, Alberta, T6G 1Z2, Canada

  • Research Site

    Brampton, Ontario, L6R 3J7, Canada

  • Research Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Montreal, Quebec, H2X 3E4, Canada

  • Research Site

    Bordeaux, 33076, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Paris, 75877, France

  • Research Site

    Villejuif, 94800, France

  • Research Site

    Berlin, 12203, Germany

  • Research Site

    Esslingen a.N., 73730, Germany

  • Research Site

    Großhansdorf, 22927, Germany

  • Research Site

    Heidelberg, 69126, Germany

  • Research Site

    Haifa, 31096, Israel

  • Research Site

    Kfar Saba, 95847, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Ramat Gan, 5265601, Israel

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Seville, 41009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.